NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Price, Forecast & Analysis
OSL:NYKD • NO0010714785
NYKD.OL Key Statistics, Chart & Performance
The current stock price of NYKD.OL is 3.568 NOK. In the past month the price increased by 29.37%. In the past year, price increased by 38.4%.
NYKD.OL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NYKD.OL. When comparing the yearly performance of all stocks, NYKD.OL is one of the better performing stocks in the market, outperforming 92.77% of all stocks.
NYKD.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL. NYKD.OL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NYKD.OL Financial Highlights
Over the last trailing twelve months NYKD.OL reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -0.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.41% | ||
| ROE | -11.09% | ||
| Debt/Equity | 0.02 |
NYKD.OL Forecast & Estimates
9 analysts have analysed NYKD.OL and the average price target is 2.24 NOK. This implies a price decrease of -37.11% is expected in the next year compared to the current price of 3.568.
For the next year, analysts expect an EPS growth of 70.24% and a revenue growth -72.85% for NYKD.OL
NYKD.OL Ownership
NYKD.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.32 | 44.408B | ||
| 1AE | ARGENX SE | 28.26 | 44.383B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.99B | ||
| 2X1 | ABIVAX SA | N/A | 8.714B | ||
| ABVX | ABIVAX SA | N/A | 8.698B | ||
| GLPG | GALAPAGOS NV | N/A | 1.902B | ||
| GXE | GALAPAGOS NV | N/A | 1.897B | ||
| IVA | INVENTIVA SA | N/A | 1.153B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.079B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About NYKD.OL
Company Profile
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 62 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Company Info
NYKODE THERAPEUTICS ASA
Oslo Science Park, Gaustadalleen 21
Oslo OSLO NO
Employees: 75
Phone: 4722958193
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What does NYKODE THERAPEUTICS ASA do?
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 62 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
What is the stock price of NYKODE THERAPEUTICS ASA today?
The current stock price of NYKD.OL is 3.568 NOK. The price decreased by -5.31% in the last trading session.
Does NYKD stock pay dividends?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a dividend yield of 25.75%. The yearly dividend amount is currently 0.
What is the ChartMill rating of NYKODE THERAPEUTICS ASA stock?
NYKD.OL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is NYKODE THERAPEUTICS ASA (NYKD.OL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NYKD.OL.
What is NYKODE THERAPEUTICS ASA worth?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a market capitalization of 1.17B NOK. This makes NYKD.OL a Small Cap stock.
What is the ownership structure of NYKODE THERAPEUTICS ASA (NYKD.OL)?
You can find the ownership structure of NYKODE THERAPEUTICS ASA (NYKD.OL) on the Ownership tab.